Achieve Life Sciences, Inc. (QUIT)

Market Cap	692.12M +192.2%
Revenue (ttm)	n/a
Net Income	-111.71M
EPS	-1.46
Shares Out	110.03M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	802,801
Open	6.42
Previous Close	6.45
Day's Range	6.20 - 6.50
52-Week Range	2.62 - 8.64
Beta	2.41
Analysts	Strong Buy
Price Target	14.58 (+131.8%)
Est. Earnings	Mar 19, 2027

About QUIT

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

• CEO: Andrew Goldberg
• Employees: 28
• Stock Exchange: Nasdaq
• Ticker Symbol: QUIT
• Website: https://www.achievelifesciences.com

Analyst Summary

According to 11 analysts, the average rating for QUIT stock is "Strong Buy." The 12-month stock price target is $14.58, which is an increase of 131.80% from the latest price.

Price Target

$14.58

(131.80% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 12, 2026

Data Sources Report a data error